Vijayan D, Smyth MJ, Teng MW (2018) Purinergic receptors: novel targets for cancer immunotherapy, in Oncoimmunology. Springer, pp 115–141

Google Scholar 

Campos-Contreras ADR, Díaz-Muñoz M, Vázquez-Cuevas FG (2020) Purinergic signaling in the hallmarks of cancer. Cells 9(7):1612

Article  CAS  PubMed  PubMed Central  Google Scholar 

Müller CE, Baqi Y, Namasivayam V (2020) Agonists and antagonists for purinergic receptors, in Purinergic Signaling. Springer, pp 45–64

Google Scholar 

Mahmood A, Iqbal J (2022) Purinergic receptors modulators: an emerging pharmacological tool for disease management. Medicinal Research Reviews

Google Scholar 

Aktories K et al (2019) cAMP guided his way: a life for G protein-mediated signal transduction and molecular pharmacology—tribute to Karl H Jakobs. Naunyn Schmiedeberg's Arch Pharmacol 392(8):887–911

Article  CAS  Google Scholar 

Burnstock G (2020) Introduction to purinergic signaling, in Purinergic Signaling. Springer, pp 1–15

Book  Google Scholar 

Faria R (2020) introductory chapter: receptors P1 and P2 as targets for drug therapy in humans, in receptors P1 and P2 as targets for drug therapy in humans. IntechOpen

Book  Google Scholar 

Borah P et al (2019) P1 receptor agonists/antagonists in clinical trials-potential drug candidates of the future. Curr Pharm Des 25(26):2792–2807

Article  CAS  PubMed  Google Scholar 

Tosh DK et al (2011) Truncated (N)-methanocarba nucleosides as A1 adenosine receptor agonists and partial agonists: overcoming lack of a recognition element. ACS Med Chem Lett 2(8):626–631

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mishra A et al (2021) P2X7 receptor in multifaceted cellular signalling and its relevance as a potential therapeutic target in different diseases. Eur J Pharmacol 906:174235

Article  CAS  PubMed  Google Scholar 

Antonioli L et al (2019) Adenosine signaling and the immune system: when a lot could be too much. Immunol Lett 205:9–15

Article  CAS  PubMed  Google Scholar 

von Kügelgen I, Hoffmann K (2016) Pharmacology and structure of P2Y receptors. Neuropharmacology 104:50–61

Article  Google Scholar 

Huang Z et al (2021) From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6(1):1–20

Article  Google Scholar 

Park J-H, Kim Y-C (2017) P2X7 receptor antagonists: a patent review (2010–2015). Expert Opin Ther Pat 27(3):257–267

Article  CAS  PubMed  Google Scholar 

Adinolfi E et al (2018) The P2X7 receptor: a main player in inflammation. Biochem Pharmacol 151:234–244

Article  CAS  PubMed  Google Scholar 

Morice AH et al (2021) Characterization of patients with refractory or unexplained chronic cough participating in a phase 2 clinical trial of the P2X3-receptor antagonist gefapixant. Lung 199(2):121–129

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedrich C et al (2020) Safety and efficacy of P2X3 antagonist BAY 1902607 in refractory chronic cough. Eur Respiratory Soc

Book  Google Scholar 

Garceau D, Chauret N (2019) BLU-5937: a selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulm Pharmacol Ther 56:56–62

Article  CAS  PubMed  Google Scholar 

Niimi A et al (2022) Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough. Eur Respir J 59(6)

Morice A et al (2021) Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J 58(5)

Illes P et al (2021) Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br J Pharmacol 178(3):489–514

Article  CAS  PubMed  Google Scholar 

Kennedy C (2015) ATP as a cotransmitter in the autonomic nervous system. Auton Neurosci 191:2–15

Article  CAS  PubMed  Google Scholar 

Hechler B et al (2003) A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med 198(4):661–667

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wéra O et al (2020) P2X1 ion channel deficiency causes massive bleeding in inflamed intestine and increases thrombosis. J Thromb Haemost 18(1):44–56

Article  PubMed  Google Scholar 

Rettinger J et al (2005) Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist. Neuropharmacology 48(3):461–468

Article  CAS  PubMed  Google Scholar 

Hülsmann M et al (2003) NF449, a novel picomolar potency antagonist at human P2X1 receptors. Eur J Pharmacol 470(1-2):1–7

Article  PubMed  Google Scholar 

Tian M et al (2020) Discovery and structure relationships of salicylanilide derivatives as potent, non-acidic P2X1 receptor antagonists. J Med Chem 63(11):6164–6178

Article  CAS  PubMed  Google Scholar 

Cockayne DA et al (2005) P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J Physiol 567(2):621–639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rong W et al (2003) Pivotal role of nucleotide P2X2 receptor subunit of the ATP-gated ion channel mediating ventilatory responses to hypoxia. J Neurosci 23(36):11315–11321

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang YA et al (2011) Knocking out P2X receptors reduces transmitter secretion in taste buds. J Neurosci 31(38):13654–13661

Article  CAS  PubMed  PubMed Central  Google Scholar 

North RA, Jarvis MF (2013) P2X receptors as drug targets. Mol Pharmacol 83(4):759–769

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finger TE et al (2005) ATP signaling is crucial for communication from taste buds to gustatory nerves. Science 310(5753):1495–1499

Article  CAS  PubMed  Google Scholar 

Baqi Y et al (2011) Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. J Med Chem 54(3):817–830

Article  CAS  PubMed  Google Scholar 

Jacobson KA et al (2006) Agonists and antagonists for P2 receptors. in Novartis Foundation symposium. NIH Public Access

Google Scholar 

Wolf C et al (2011) Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking. Mol Pharmacol 79(4):649–661

Article  CAS  PubMed  Google Scholar 

Schneider R et al (2021) A novel P2X2-dependent purinergic mechanism of enteric gliosis in intestinal inflammation. EMBO Mol Med 13(1):e12724

Article  CAS  PubMed  Google Scholar 

Carter DS et al (2009) Identification and SAR of novel diaminopyrimidines. Part 1: the discovery of RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain. Bioorg Med Chem Lett 19(6):1628–1631

Article  CAS  PubMed  Google Scholar 

Ballini E et al (2011) Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model. Br J Pharmacol 163(6):1315–1325

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inoue K (2019) Role of the P2X4 receptor in neuropathic pain. Curr Opin Pharmacol 47:33–39

Article  CAS  PubMed  Google Scholar 

Bragança B, Correia-de-Sá P (2020) Resolving the ionotropic P2X4 receptor mystery points towards a new therapeutic target for cardiovascular diseases. Int J Mol Sci 21(14):5005

Article  PubMed  PubMed Central  Google Scholar 

Gum RJ, Wakefield B, Jarvis MF (2012) P2X receptor antagonists for pain management: examination of binding and physicochemical properties. Purinergic Signal 8(1):41–56

Article  CAS  PubMed  Google Scholar 

Hernandez-Olmos V et al (2012) N-substituted phenoxazine and acridone derivatives: structure–activity relationships of potent P2X4 receptor antagonists. J Med Chem 55(22):9576–9588

Article  CAS  PubMed  Google Scholar 

Matsumura Y et al (2016) A novel P2X4 receptor-selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain. Sci Rep 6(1):1–11